Antibody News and Research RSS Feed - Antibody News and Research

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.
Study provides proof of concept for developing antibodies against human pathogens

Study provides proof of concept for developing antibodies against human pathogens

Scientists investigating the potentially deadly hantavirus have used a novel approach to developing protective antibodies against it. Their work, published in today's online edition of Science Translational Medicine, provides proof of concept for producing antibodies against a broad range of human pathogens. [More]
Experimental drug works best when patients' immune cells surrounding tumors express PD-L1

Experimental drug works best when patients' immune cells surrounding tumors express PD-L1

A promising experimental immunotherapy drug works best in patients whose immune defenses initially rally to attack the cancer but then are stymied by a molecular brake that shuts down the response, according to a new study led by researchers at Dana-Farber Cancer Institute and the Yale University School of Medicine. [More]
Lithium therapy duration not linked to thyroid effects

Lithium therapy duration not linked to thyroid effects

The risk of altered thyroid function does not increase with duration of lithium treatment in patients with bipolar disorder, research suggests. [More]
Ebola vaccine shows promising results in human trial

Ebola vaccine shows promising results in human trial

An experimental vaccine against the Ebola virus has proved effective and well-tolerated in the first human trial of a candidate Ebola drug. [More]
Immune Pharmaceuticals closes underwriter's exercise of partial over-allotment option of 459,697 units

Immune Pharmaceuticals closes underwriter's exercise of partial over-allotment option of 459,697 units

Immune Pharmaceuticals Inc., a clinical stage biopharmaceutical company that engages in the development and commercialization of targeted therapeutics for the treatment of inflammatory diseases and cancer, today completed the underwriter's exercise of partial over-allotment option of 459,697 units, at a price of $2.50 per unit, for gross proceeds of approximately $1.06 million, bringing the aggregate gross proceeds of the Company's previously announced underwritten public offering to $9.685 million. [More]
Experimental Ebola vaccine appears safe, produces immune system responses in NIH phase 1 trial

Experimental Ebola vaccine appears safe, produces immune system responses in NIH phase 1 trial

An experimental vaccine to prevent Ebola virus disease was well-tolerated and produced immune system responses in all 20 healthy adults who received it in a Phase 1 clinical trial conducted by researchers from the National Institutes of Health. The candidate vaccine, which was co-developed by the NIH's National Institute of Allergy and Infectious Diseases and GlaxoSmithKline, was tested at the NIH Clinical Center in Bethesda, Maryland. [More]
Scientists make breakthrough in developing new treatment for advanced bladder cancer

Scientists make breakthrough in developing new treatment for advanced bladder cancer

Scientists from Queen Mary University of London have made a breakthrough in developing a new therapy for advanced bladder cancer - for which there have been no major treatment advances in the past 30 years. [More]
CARsgen announces completion of series A financing

CARsgen announces completion of series A financing

CARsgen, a leader in the development of Chimeric Antigen Receptors T (CAR-T) cell immunotherapy to treat a variety of cancers, today announced the completion of a series A financing led by BVCF, a China-based healthcare private equity fund. [More]
Oxford BioTherapeutics, Menarini Group initiate phase I study of OBT357 (MEN1112) for AML treatment

Oxford BioTherapeutics, Menarini Group initiate phase I study of OBT357 (MEN1112) for AML treatment

Oxford BioTherapeutics and Berlin Chemie/ Menarini Biotech/ Menarini Ricerche (belonging to Menarini Group) announce today that they have initiated the first-in-human clinical study of OBT357 (MEN1112), a novel enhanced antibody for the treatment of acute myeloid leukemia (AML). [More]
Johns Hopkins researchers develop online tool to speed up creation of new drugs to prevent Ebola virus

Johns Hopkins researchers develop online tool to speed up creation of new drugs to prevent Ebola virus

Johns Hopkins biomedical engineers have developed a free, browser-based online tool that could speed up the creation of new drugs to treat or prevent Ebola virus infections. [More]
Researchers discover why only some patients respond to ipilimumab drug

Researchers discover why only some patients respond to ipilimumab drug

A collaborative team of leaders in the field of cancer immunology from Memorial Sloan Kettering Cancer Center has made a key discovery that advances the understanding of why some patients respond to ipilimumab, an immunotherapy drug, while others do not. MSK was at the forefront of the clinical research that brought this CTLA-4 blocking antibody to melanoma patients. [More]
Hydroxyurea therapy offers safe, effective disease management of SCA

Hydroxyurea therapy offers safe, effective disease management of SCA

Conclusive data show that hydroxyurea therapy offers safe and effective disease management of sickle cell anemia (SCA) and reduces the risk of stroke, prompting early termination by the National Heart Lung and Blood Institute of a key clinical trial studying the drug's efficacy. [More]
Researchers identify genetic signatures in melanoma tumors that predict response to immunotherapy

Researchers identify genetic signatures in melanoma tumors that predict response to immunotherapy

A team led by Ludwig and Memorial Sloan Kettering (MSK) researchers has published a landmark study on the genetic basis of response to a powerful cancer therapy known as immune checkpoint blockade. [More]
'Spillover' of henipaviruses into humans underway, study finds

'Spillover' of henipaviruses into humans underway, study finds

Another family of viruses, deadly in some cases, may have already jumped from fruit bats into humans in Africa, according to a study published today in the journal Nature Communications. The study provides the first, preliminary scientific evidence that "spillover" of henipaviruses into human populations is underway. [More]
TSRI scientists reveal how ZMapp antibodies target Ebola virus

TSRI scientists reveal how ZMapp antibodies target Ebola virus

Scientists at The Scripps Research Institute have identified weak spots on the surface of Ebola virus that are targeted by the antibodies in ZMapp, the experimental drug cocktail administered to several patients during the recent Ebola outbreak. [More]
3SBio enters into exclusive license agreement with PharmAbcine for Tanibirumab

3SBio enters into exclusive license agreement with PharmAbcine for Tanibirumab

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive license with PharmAbcine, Inc. for the development, manufacturing and marketing of Tanibirumab, an anti-VEGFR2/KDR antibody for cancer in the territory of Greater China (including Mainland China, Taiwan, Hong Kong and Macau) and several emerging countries, including Thailand, Brazil and Russia. [More]
Three-day global symposium on Ebola virus, other infectious diseases

Three-day global symposium on Ebola virus, other infectious diseases

The 11th annual International Consortium on Anti-Virals (ICAV) symposium, Infectious Diseases: Global Public-Health Challenges of the Next Decade, will put the challenges posed by several infectious diseases under the microscope, including the Ebola virus, the H7N9 influenza virus, MERS coronavirus and dengue viruses, as well as drug-resistant tuberculosis. [More]
Researchers discover second protein associated with membranous nephropathy

Researchers discover second protein associated with membranous nephropathy

An international team of researchers from France, Germany, and the US have identified a protein that turns a person's immune system against itself in a form of kidney disease called membranous nephropathy (MN). The new research was presented at ASN Kidney Week 2014 in Philadelphia and published online in the New England Journal of Medicine. [More]
PDL BioPharma receives $30.3M to conclude revenue interest contract with AxoGen

PDL BioPharma receives $30.3M to conclude revenue interest contract with AxoGen

PDL BioPharma, Inc. (PDL) today announced that the company has received $30.3 million, in addition to previously received revenue interest payments, to conclude PDL's revenue interest agreement with AxoGen, Inc. [More]
Experimental Ebola treatments to be trialled in West Africa next month

Experimental Ebola treatments to be trialled in West Africa next month

Médecins Sans Frontières/Doctors without Borders (MSF) have announced that three trials of Ebola therapies will begin in West Africa this December. [More]